RT Journal Article
T1 Study of plasma anti-CD26 autoantibody levels in a cohort of treatment-naïve early arthritis patients
A1 Cordero Santamaría, Óscar Javier
A1 Viéitez González, Irene
A1 Altabás González, Irene
A1 Nuño Nuño, Laura
A1 Villalba Yllán, Alejandro
A1 Novella Navarro, Marta
A1 Peiteado López, Diana
A1 Miranda-Carús, María-Eugenia
A1 Balsa Criado, Alejandro
A1 Varela Calviño, Rubén
A1 Gómez Touriño, Iria María
A1 Pego Reigosa, José María
K1 Autoantibodies
K1 CD26
K1 Anti-CD26
K1 Early rheumatoid arthritis
K1 Autoimmunity
K1 Etiology
AB In rheumatoid arthritis (RA), the identifcation of biomarkers to adjust treatment intensity and to correctly diagnose the disease in early stages still constitutes a challenge and, as such, novel biomarkers are needed. We proposed that autoantibodies(aAbs) against CD26 (DPP4) might have both etiological importance and clinical value. Here, we perform a prospectivestudy of the potential diagnostic power of Anti-CD26 aAbs through their quantifcation in plasmas from 106 treatment-naïveearly and undiferentiated AR. Clinical antibodies, Anti-CD26 aAbs, and other disease-related biomarkers were measuredin plasmas obtained in the frst visit from patients, which were later classifed as RA and non-RA according to the AmericanCollege of Rheumatology criteria. Two diferent isotype signatures were found among ten groups of patients, one for AntiCD26 IgA and other for Anti-CD26 IgG and IgM isotypes, both converging in patients with arthritis (RA and UnresolvedUndiferentiated Arthritis: UUA), who present elevated levels of all three isotypes. The four UUA patients, unresolved aftertwo years, were ACPA and rheumatic factor (RF) negatives. In the whole cohort, 51.3% of ACPA/RF seronegatives wereAnti-CD26 positives, and a similar frequency was observed in the seropositive RA patients. Only weak associations of thethree isotypes with ESR, CRP and disease activity parameters were observed. Anti-CD26 aAbs are present in treatmentnaïve early arthritis patients, including ACPA and RF seronegative individuals, suggestive of a potential pathogenic and/orbiomarker role of Anti-CD26 aAbs in the development of rheumatic diseases
PB Springer
SN 0004-069X
YR 2022
FD 2022
LK http://hdl.handle.net/10347/29165
UL http://hdl.handle.net/10347/29165
LA eng
NO Archivum Immunologiae et Therapiae Experimentalis 70, 12 (2022). https://doi.org/10.1007/s00005-022-00649-6
NO Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by the European Union (Interreg V-A Spain-Portugal Cooperative Program (POCTEP), the Health Research Institute Carlos III (ISCIII/PI21/00370/Cofinanciado por la Unión Europea/FEDER), and 0227_CodigoMais_1_E, USC-SERGAS Cooperation 2018–2019
DS Minerva
RD 24 abr 2026